United States
Premiumsupplier
Carisbamate (RWJ-333369) CAS NO.194085-75-1
- Min.Order: 1 Gram
- Payment Terms: L/C
- Product Details
Keywords
- (1S)-1-(2-Chlorophenyl)-1,2-ethanediol 2-Carbamate
- JNJ 10234094
- RWJ 333369
Quick Details
- ProName: Carisbamate (RWJ-333369)
- CasNo: 194085-75-1
- Molecular Formula: C9H10ClNO3
- Appearance: White Solid
- Application: Carisbamate (YKP 509, proposed trade n...
- DeliveryTime: 7 days
- PackAge: inquiry
- Port: inquiry
- ProductionCapacity: 10 Kilogram/Month
- Purity: > 95%
- Storage: 10kg
- Transportation: inquiry
- LimitNum: 1 Gram
Superiority
BOC Sciences is committed to supplying cost-effective products and services. We provide Carisbamate (RWJ-333369). Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown. More information please visit: www.bocsci.com/carisbamate-rwj-333369-cas-194085-75-1-item-468174.html
Details
BOC Sciences is committed to supplying cost-effective products and services. We provide Carisbamate (RWJ-333369). Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown. More information please visit: www.bocsci.com/carisbamate-rwj-333369-cas-194085-75-1-item-468174.html